CARGO Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering innovative chimeric antigen receptor (CAR) T-cell therapies for patients battling cancer. Its primary therapeutic candidate is CRG-022, an autologous CD22 CAR T-cell product. This therapy is specifically engineered to counteract mechanisms of resistance in B-cell malignancies by targeting CD22, a distinct tumor antigen prevalent in these conditions.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2025 | -$0.38 | -$0.27 | Beat |
| May 8, 2025 | -$0.70 | -$1.77 | Miss |
| Mar 12, 2025 | -$0.95 | -$0.95 | Beat |
| Nov 12, 2024 | -$1.14 | -$0.88 | Beat |
| Aug 12, 2024 | -$1.06 | -$1.02 | Beat |
| May 14, 2024 | -$1.05 | -$0.87 | Beat |